Yoon Hang Kim, MD, MPH

Board Certified in Preventive Medicine | Integrative & Functional Medicine

|  March 2026

Abstract

Medicinal mushrooms have attracted widespread consumer and clinical interest as “immune boosters,” but the immunological reality is far more nuanced than popular marketing suggests. Compounds such as β-glucans, terpenes, lectins, and fungal immunomodulatory proteins can activate macrophages, dendritic cells, natural killer cells, and both T and B lymphocytes—but they can also down-regulate certain immune pathways depending on species, dose, preparation, and the underlying immunological state of the patient. For individuals living with autoimmune conditions, this bidirectional immunomodulatory capacity creates both therapeutic opportunity and serious clinical risk. Experimental evidence demonstrates that certain β-glucan polysaccharides can ameliorate autoimmune inflammation in animal models of psoriasis and arthritis through macrophage-mediated mechanisms. However, case reports and outbreak data have linked mushroom supplement use to flares of HMGCR immune-mediated necrotizing myopathy (IMNM), a rare but serious autoimmune myositis, owing to the natural HMG-CoA reductase–inhibiting activity found in several edible mushroom species. Meanwhile, low-dose naltrexone (LDN) has emerged as a predictable, well-tolerated immune modulator with a growing evidence base across multiple autoimmune and chronic inflammatory conditions. This article examines the immunology of medicinal mushrooms in the context of autoimmune disease, compares their risk–benefit profile to LDN, and offers practical clinical guidance for the integrative practitioner navigating the increasingly complex landscape of post-COVID immune dysregulation.

How Mushrooms Affect Immunity

The medicinal mushroom category encompasses a diverse pharmacopoeia of species—reishi (Ganoderma lucidum), turkey tail (Trametes versicolor), chaga (Inonotus obliquus), lion’s mane (Hericium erinaceus), shiitake (Lentinula edodes), and maitake (Grifola frondosa)—each containing a distinct profile of bioactive compounds. The principal immunoactive constituents include β-glucan polysaccharides (particularly β-1,3 and β-1,6 linked glucans), triterpenes, lectins, and fungal immunomodulatory proteins (FIPs). These compounds engage pattern recognition receptors on innate immune cells, most notably Dectin-1 and complement receptor 3 (CR3) on macrophages, dendritic cells, and neutrophils. Upon binding, β-glucans trigger downstream signaling through NF-κB and other inflammatory cascades, resulting in cytokine secretion (IL-1β, IL-6, TNF-α), enhanced phagocytic activity, and activation of adaptive immune responses through T-cell and B-cell engagement.

Crucially, this immunological effect is not uniformly stimulatory. Research published in Nature Immunology has demonstrated that β-glucan can reprogram neutrophils toward a regulatory phenotype that promotes disease tolerance rather than unbridled inflammation—a finding that challenges the simplistic “immune booster” narrative. Furthermore, the net immunological impact depends heavily on the structural conformation of the β-glucan (linkage pattern, molecular weight, branching frequency), the route and dose of administration, and the immunological baseline of the host. This context-dependence is precisely what makes mushrooms simultaneously interesting and hazardous in autoimmune disease.

Potential Benefits in Autoimmune Disease

A growing body of preclinical research suggests that certain mushroom-derived polysaccharides may exert beneficial immunomodulatory effects relevant to autoimmunity. A notable 2022 study published in Scientific Reports demonstrated that three common β-glucan variants (1,6-β-glucan, 1,3-β-glucan, and 1,3-1,6-β-glucan) could down-regulate disease activity in a mannan-induced psoriasis and psoriatic arthritis mouse model. The protective effect was dependent on the macrophage mannose receptor (CD206) and was more pronounced with long-term than short-term exposure. Importantly, at the doses tested, the β-glucans did not induce arthritis, psoriasis, or psoriatic arthritis in wild-type mice—they could only ameliorate existing disease, suggesting a genuine therapeutic rather than purely immunostimulatory mechanism.

Additional preclinical and review-level evidence points to mushroom polysaccharides influencing T-cell polarization, potentially supporting regulatory T-cell (Treg) function and rebalancing Th1/Th2 ratios—both of which are directly relevant to autoimmune pathogenesis. Reishi and chaga have been highlighted in the integrative medicine literature for their anti-inflammatory and antioxidant properties, with traditional use data and modern pharmacological analyses suggesting benefits for the chronic, low-grade inflammation that underlies many autoimmune conditions. The prebiotic effects of certain mushroom polysaccharides on gut microbiota represent another indirect but clinically meaningful mechanism, given the well-established role of intestinal dysbiosis in autoimmune disease initiation and perpetuation.

Risks and Reported Flares

Despite the promising preclinical data, the clinical literature contains serious cautionary signals that demand careful attention from integrative practitioners. The most striking example involves HMGCR immune-mediated necrotizing myopathy (IMNM), a rare autoimmune myositis associated with autoantibodies targeting the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase. While this condition was initially recognized in patients with statin exposure, a 2022 case report published in BMJ Case Reports documented the first definitive flare of established HMGCR IMNM triggered by mushroom supplements in a woman in her thirties with no history of statin use. The patient’s creatine kinase levels rose significantly after initiating a mushroom supplement regimen (containing shiitake, maitake, and reishi) and returned to baseline after discontinuation alone, without any additional immunosuppressive intervention.

This case is particularly instructive because it demonstrates a mechanistic link between the natural HMG-CoA reductase–inhibiting activity found in several edible mushroom species and the triggering of an autoimmune cascade. The prevalence of statin-naïve anti-HMGCR IMNM is notably higher in East Asia compared with North America, and this geographic disparity has been attributed to dietary differences in mushroom consumption as well as other natural HMGCR inhibitors such as red yeast rice and pu’erh tea.

Beyond the HMGCR-IMNM risk, broader clinical guidance cautions against the use of strongly immune-stimulating mushroom products in patients with active systemic autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Lion’s mane, in particular, has been flagged as potentially problematic in this patient population due to its capacity to enhance immune cell activity. The fundamental problem is that many mushroom supplements are marketed as “immune boosters”—a framework that is precisely wrong for the autoimmune patient, whose immune system is already overactive in harmful, self-directed ways.

LDN: An Immune Modulator Par Excellence

In contrast to the variable and sometimes unpredictable immunomodulatory effects of mushroom supplements, low-dose naltrexone (LDN) offers a more predictable, well-characterized, and reproducible approach to immune modulation. Originally approved by the FDA in 1984 for the treatment of opioid addiction at standard doses (50 mg), naltrexone at low doses (typically 1.5–4.5 mg) acts through a fundamentally different pharmacological mechanism: transient opioid receptor blockade that triggers a compensatory upregulation of endogenous endorphin and enkephalin production. Because immune cells express opioid receptors, this endorphin surge has downstream immunomodulatory effects, including enhancement of regulatory T-cell function and modulation of toll-like receptor 4 (TLR-4) signaling on glial cells and macrophages.

The distinction between “immune stimulation” and “immune regulation” is critical here. LDN does not simply boost or suppress immunity—it recalibrates the immune system toward homeostasis. This makes it fundamentally different from both conventional immunosuppressants (which blunt the immune response globally) and immune stimulants (which amplify it indiscriminately). For the autoimmune patient, this regulatory rather than suppressive mechanism is precisely what is needed: dampening the self-directed immune attack while preserving the capacity for appropriate immune surveillance against infection and malignancy.

The clinical evidence base for LDN in autoimmune and inflammatory conditions has expanded significantly. Published trials and case series demonstrate efficacy in Crohn’s disease (with mucosal healing rates exceeding 70% in some studies), multiple sclerosis (reduced fatigue and improved quality of life), fibromyalgia (significant pain reduction in multiple placebo-controlled trials), and rheumatoid arthritis (decreased pain and inflammatory markers). Emerging data also support LDN’s role in Long COVID and chronic fatigue syndrome, with studies reporting decreased fatigue, normalized sleep patterns, and improved functional status. Across all these conditions, LDN consistently demonstrates a remarkably favorable safety profile, with side effects limited primarily to vivid dreams and occasional transient insomnia.

It is important to acknowledge that LDN does not work for every patient in every condition. Response rates are condition-dependent—for example, the response rate in tinnitus is approximately 30%, which, while modest, still exceeds the efficacy of many conventional alternatives that approach 0% for this notoriously refractory symptom. The placebo effect also varies by condition: strong in pain-related disorders like low back pain, but weak in complex neurological conditions like tinnitus, reinforcing the importance of treatments with genuine physiological mechanisms of action.

LDN Versus Mushroom Supplements: A Clinical Comparison

The following comparison highlights the practical clinical differences between LDN and mushroom supplements as immunomodulatory strategies in the autoimmune patient population.

The table above underscores a fundamental clinical reality: while both LDN and mushroom supplements are described as “immunomodulators,” their pharmacological behavior, predictability, safety profiles, and evidence bases differ markedly. For the integrative clinician managing autoimmune disease, LDN offers a more controlled and reproducible therapeutic lever, while mushroom supplements require significantly more caution, individualization, and monitoring.

The Post-COVID Landscape: Why This Matters Now

The relevance of this comparison has been amplified by the post-COVID clinical landscape. Clinicians across integrative, functional, and conventional medicine are observing an unprecedented convergence of immune dysregulation syndromes: mast cell activation syndrome (MCAS) overlapping with postural orthostatic tachycardia syndrome (POTS), dysautonomia co-occurring with chronic fatigue, and Long COVID presenting with features of all of the above. This overlapping, multi-system immune dysregulation represents a qualitative shift in the complexity of chronic disease that has rendered many traditional treatment algorithms inadequate.

In this environment, the allure of “natural immune support” through mushroom supplements is understandable but potentially dangerous. Patients with MCAS, for example, may react to mushroom-derived compounds through histamine-mediated or mast cell–degranulation pathways that are entirely distinct from the intended immunomodulatory mechanism. Patients with active autoimmune components of their dysregulation may experience immune stimulation from mushroom products at precisely the moment when immune calming is required. The immunological fragility of the post-COVID patient demands therapeutic precision, not broad-spectrum immune stimulation.

LDN, by contrast, fits more naturally into the post-COVID treatment paradigm. Its TLR-4 modulation directly addresses neuroinflammation and microglial activation—both of which are increasingly recognized as central to Long COVID pathophysiology. Its Treg-enhancing properties support immune rebalancing without the risk of immune overstimulation. And its favorable side-effect profile allows for safe combination with other interventions commonly used in this population, including mast cell stabilizers, antihistamines, and autonomic support agents.

Practical Clinical Guidance

For Mushroom Supplements in Autoimmune Patients

Mushrooms should be viewed as immunomodulatory rather than uniformly safe. Effects vary by species, dose, preparation, and underlying disease activity. Limited human data and rare but serious adverse events argue for careful risk–benefit assessment. Patients with known HMGCR-IMNM should strictly avoid all mushroom supplements, and dietary mushroom restriction should be considered. In patients on immunosuppressants or with highly active systemic autoimmunity, strongly immune-stimulating products should be avoided. If a clinician elects to trial mushroom-based therapy—for example, reishi or turkey tail for anti-inflammatory or gut-modulating effects—it is prudent to start at the lowest effective dose, monitor disease activity markers and relevant labs at regular intervals, and document the specific species, dose, preparation, and source.

For LDN in Autoimmune and Complex Chronic Disease

LDN remains one of the safest and most versatile immune modulators available to the integrative clinician. It should be compounded by a pharmacy experienced with LDN (avoiding slow-release formulations and calcium carbonate fillers), initiated at a low starting dose (typically 0.5–1.5 mg at bedtime), and titrated gradually to the therapeutic range of 1.5–4.5 mg based on clinical response and tolerability. Dosing at bedtime (around 9–10 PM) optimizes the pharmacological interaction with the circadian endorphin cycle. Monitoring should include baseline and follow-up inflammatory markers, disease-specific activity indices, and symptom tracking.

A Note on Clinical Philosophy

Modern chronic disease—especially in the post-COVID era—demands flexible thinking, personalized treatment, and continuous adaptation. Not all “natural” therapies are safe in autoimmune disease, and not all pharmaceutical interventions are harmful. The clinician’s obligation is to match the therapeutic mechanism to the patient’s immunological reality, not to a marketing narrative or ideological framework. Static protocols become outdated quickly in a landscape where disease patterns themselves are evolving. The prepared clinician is the one who remains humble before the complexity of human immunology while using the best available evidence—and the safest available tools—to guide each patient’s individual journey.

About the Author

Yoon Hang Kim, MD, MPH, is a board-certified physician in Preventive Medicine and Integrative & Holistic Medicine. He is a Certified Medical Acupuncturist (UCLA), Osher Fellow (University of Arizona Center for Integrative Medicine), and IFM Scholar with over 20 years of clinical experience in integrative and functional medicine. Dr. Kim is a recognized expert on low-dose naltrexone, having authored multiple books and articles on the subject, and leads the LDN Support Group (7,000+ members). His membership-based telemedicine practice, Direct Integrative Care (www.directintegrativecare.com), serves patients across six states. He also practices at Hill Country Integrative Medicine in Fredericksburg, Texas. Professional website: yoonhangkim.com | LDN community: LDNSupportGroup.com

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Autoimmune disease management should be conducted in partnership with qualified healthcare providers who understand your individual clinical situation.

References

1. Rodahl, E., Stand, V., Gundersen, T., & Holmdahl, R. (2022). Variants of beta-glucan polysaccharides downregulate autoimmune inflammation. Scientific Reports, 12, 8065. https://doi.org/10.1038/s41598-022-11708-x

2. Adler, B., Christopher-Stine, L., & Tiniakou, E. (2022). Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy. BMJ Case Reports, 15(5), e248880. https://doi.org/10.1136/bcr-2022-248880

3. Khoo, T., & Chinoy, H. (2023). Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues. Autoimmunity Reviews, 22(12), 103468. https://doi.org/10.1016/j.autrev.2023.103468

4. Li, Z., You, Y., Griffin, N., Feng, J., & Shan, F. (2018). Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology, 61, 178–184. https://doi.org/10.1016/j.intimp.2018.06.004

5. Teymoori-Rad, M., et al. (2025). Therapeutic uses and efficacy of low-dose naltrexone: A scoping review. Cureus. https://doi.org/10.7759/cureus.79449

6. Gil-Ramírez, A., et al. (2013). Screening of edible mushrooms and extraction by pressurized water of 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitors. Journal of Functional Foods, 5(1), 244–250.

7. Suh, J. P., & Dimachkie, M. M. (2024). Management of immune-mediated necrotizing myopathy. Muscle & Nerve, 70(2), 166–172. https://doi.org/10.1002/mus.28114

8. Moreira Lopes, T. C., et al. (2023). Low-dose naltrexone in rheumatological diseases. Frontiers in Medicine, 10, 1149533. https://doi.org/10.3389/fmed.2023.1149533

9. Sahasrabudhe, N. M., et al. (2021). Immunomodulating effects of fungal beta-glucans: From traditional use to medicine. Nutrients, 13(4), 1333. https://doi.org/10.3390/nu13041333

10. Brown, G. D., & Gordon, S. (2005). Immune recognition of fungal β-glucans. Cellular Microbiology, 7(4), 471–479.

11. Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459.

12. Brown, N., & Panksepp, J. (2009). Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses, 72(3), 333–337. https://doi.org/10.1016/j.mehy.2008.06.048

13. Yoshida, T., Chikazawa, H., & Kumon, Y. (2023). Did shiitake mushrooms induce immune-mediated necrotizing myopathy? The Rheumatologist.

14. Çetin, H., et al. (2025). β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus. Nature Immunology, 26, 424–436. https://doi.org/10.1038/s41590-024-02041-2